Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Knop

Showing results (61-70 of 508) with videos related to

Pageof 51
Sort By:
Mayo Clinic Proceedings|January 9, 2018
The Role of Glucagon in the Pathophysiology and Treatment of Type 2 DiabetesSofie Hædersdal, Asger Lund, Filip K Knop, et al.
Diabetes, Obesity & Metabolism|May 11, 2016
Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'M A Skow, N C Bergmann, F K Knop
Nature Reviews. Endocrinology|May 6, 2018
Glucagon-like peptide 1 in health and diseaseAndreas Andersen, Asger Lund, Filip K Knop, et al.
Nature Reviews. Endocrinology|March 18, 2023
Revisiting the role of glucagon in health, diabetes mellitus and other metabolic diseasesSofie Hædersdal, Andreas Andersen, Filip K Knop, et al.
Diabetes, Obesity & Metabolism|January 29, 2016
Effect of antibiotics on gut microbiota, glucose metabolism and body weight regulation: a review of the literatureK H Mikkelsen, K H Allin, F K Knop
Frontiers in Endocrinology|December 3, 2021
Editorial: Proglucagon-Derived PeptidesPeter R Flatt, Filip K Knop, Andrei I Tarasov
International Journal of Molecular Sciences|August 10, 2024
Comment on Yang et al. Bile Acid Diarrhea: From Molecular Mechanisms to Clinical Diagnosis and Treatment in the Era of Precision Medicine. <i>Int. J. Mol. Sci.</i> 2024, <i>25</i>, 1544Anne-Marie Ellegaard, Martin L Kårhus, Filip K Knop
Expert Opinion on Investigational Drugs|March 12, 2011
Lixisenatide for type 2 diabetes mellitusMikkel Christensen, Filip K Knop, Tina Vilsbøll, et al.
Journal of Pharmaceutical and Biomedical Analysis|March 5, 2013
Development and in-line validation of a Process Analytical Technology to facilitate the scale up of coating processesM Wirges, A Funke, P Serno, et al.
Expert Opinion on Drug Safety|November 4, 2014
Adverse drug reactions associated with the use of liraglutide in patients with type 2 diabetes--focus on pancreatitis and pancreas cancerThor Chalmer, Thomas P Almdal, Tina Vilsbøll, et al.
Pageof 51

Showing results (61-70 of 508) with videos related to

Sort By:
Pageof 51
Mayo Clinic Proceedings|January 9, 2018
The Role of Glucagon in the Pathophysiology and Treatment of Type 2 DiabetesSofie Hædersdal, Asger Lund, Filip K Knop, et al.
Diabetes, Obesity & Metabolism|May 11, 2016
Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'M A Skow, N C Bergmann, F K Knop
Nature Reviews. Endocrinology|May 6, 2018
Glucagon-like peptide 1 in health and diseaseAndreas Andersen, Asger Lund, Filip K Knop, et al.
Nature Reviews. Endocrinology|March 18, 2023
Revisiting the role of glucagon in health, diabetes mellitus and other metabolic diseasesSofie Hædersdal, Andreas Andersen, Filip K Knop, et al.
Diabetes, Obesity & Metabolism|January 29, 2016
Effect of antibiotics on gut microbiota, glucose metabolism and body weight regulation: a review of the literatureK H Mikkelsen, K H Allin, F K Knop
Frontiers in Endocrinology|December 3, 2021
Editorial: Proglucagon-Derived PeptidesPeter R Flatt, Filip K Knop, Andrei I Tarasov
International Journal of Molecular Sciences|August 10, 2024
Comment on Yang et al. Bile Acid Diarrhea: From Molecular Mechanisms to Clinical Diagnosis and Treatment in the Era of Precision Medicine. <i>Int. J. Mol. Sci.</i> 2024, <i>25</i>, 1544Anne-Marie Ellegaard, Martin L Kårhus, Filip K Knop
Expert Opinion on Investigational Drugs|March 12, 2011
Lixisenatide for type 2 diabetes mellitusMikkel Christensen, Filip K Knop, Tina Vilsbøll, et al.
Journal of Pharmaceutical and Biomedical Analysis|March 5, 2013
Development and in-line validation of a Process Analytical Technology to facilitate the scale up of coating processesM Wirges, A Funke, P Serno, et al.
Expert Opinion on Drug Safety|November 4, 2014
Adverse drug reactions associated with the use of liraglutide in patients with type 2 diabetes--focus on pancreatitis and pancreas cancerThor Chalmer, Thomas P Almdal, Tina Vilsbøll, et al.
Pageof 51